source
- Podcast explores emerging rapid‑acting and psychedelic therapies for treatment‑resistant depressionIn a recent episode of BioSpace’s Denatured podcast, host Jennifer C. Smith‑Parker talks with Hans Eriksson, chief medical officer of FundaMental Pharma, and Steve Levine, chief patient officer at…
- Context Therapeutics drops CT-95 bispecific T-cell engager to stretch cash runway to 2027Context Therapeutics announced it is halting development of its bispecific T-cell engager CT-95. The company acquired CT-95 in 2024 for $3.7 million and began dosing patients in a phase 1 trial in…